Recombinant Mouse Prostaglandin E2 receptor EP2 subtype (Ptger2)

What is the structure and functional role of mouse Ptger2?

Mouse Prostaglandin E2 receptor EP2 subtype (Ptger2) is a 362 amino acid G protein-coupled receptor belonging to the prostanoid receptor family. It is characterized by seven transmembrane domains typical of GPCRs and functions primarily by coupling to Gs proteins, leading to adenylyl cyclase stimulation and increased intracellular cAMP levels . The principal endogenous ligand is PGE2, with PGE1 having similar potency, followed by PGF2α and PGI2, with the potency order being: PGE2 = PGE1 > PGF2α, PGI2 > PGD2, thromboxane A2 .

Ptger2 plays crucial roles in numerous physiological processes including inflammation, immune regulation, and cancer progression. In cancer contexts specifically, activation of Ptger2 can restrict the proliferative expansion and effector differentiation of TCF1+ CD8+ T cells, potentially promoting tumor immune escape . This receptor is therefore emerging as an important target for immunotherapeutic approaches in cancer treatment.

How does mouse Ptger2 differ from human PTGER2?

Mouse Ptger2 consists of the full 362 amino acids, while human PTGER2 comprises 358 amino acids . Despite this difference in length, they share high sequence homology, particularly in the transmembrane domains and intracellular loops involved in G protein coupling. The most notable structural differences occur in the N-terminal extracellular domain and the C-terminal region.

What signaling pathways are activated by mouse Ptger2?

Mouse Ptger2 activation primarily engages the Gs/adenylyl cyclase/cAMP/PKA pathway . Upon binding of PGE2, Ptger2 undergoes a conformational change that facilitates coupling to Gs proteins, which subsequently activate adenylyl cyclase to increase intracellular cAMP levels. This elevated cAMP then activates protein kinase A (PKA), leading to phosphorylation of various downstream targets including the cyclic AMP response element-binding protein (CREB) .

Phosphorylated CREB translocates to the nucleus where it regulates gene expression of multiple targets. In keratinocytes, this pathway promotes cell proliferation and cyclooxygenase-2 (COX-2) expression, establishing a positive feedback loop between PGE2 production and EP2 signaling . The PKA/CREB pathway is crucial for mediating many of the biological effects of EP2 activation in various cellular contexts.

In T cells specifically, EP2 signaling can modulate IL-2 responsiveness, affecting their proliferation and differentiation in the tumor microenvironment . This modulation appears to be a key mechanism by which tumor-derived PGE2 can suppress effector T cell functions and promote immune evasion.

What expression systems are optimal for producing functional recombinant mouse Ptger2?

For producing functional recombinant mouse Ptger2, mammalian expression systems generally yield the most physiologically relevant protein. Based on available research, HEK-293 cells represent one of the most commonly used and effective expression systems for recombinant Ptger2 production . These cells provide the necessary cellular machinery for proper protein folding, post-translational modifications, and membrane insertion of this GPCR.

When designing expression constructs, researchers should consider incorporating appropriate purification tags. Various tags can be utilized including His tags, Strep tags, and Fc fusion tags, with placement preferentially at the C-terminus to avoid interfering with the N-terminal ligand-binding domain . The addition of a signal peptide can enhance membrane targeting, while codon optimization for mammalian expression may improve yields.

For functional studies, cell-free protein synthesis (CFPS) systems have also been employed successfully for producing recombinant Ptger2 . This approach allows for rapid production and can be particularly useful for initial screening studies or when attempting to express difficult membrane proteins.

Regardless of the expression system selected, validation of functional activity through appropriate assays (ligand binding, signaling activation) is essential to confirm that the recombinant protein retains native properties.

What pharmacological tools specifically target mouse Ptger2?

Several pharmacological tools exhibit high specificity for mouse Ptger2 in experimental settings:

For selective activation of EP2 receptors, ONO-AE1-259 is considered the agonist of choice due to its high selectivity over other EP receptor subtypes . Butaprost and its free acid form are also widely used EP2-selective agonists, although they require enzymatic hydrolysis of their ester moiety to achieve full bioactivity and may show some activity at higher concentrations at other EP receptors . CP-533536 represents a non-prostanoid EP2 receptor agonist with good selectivity profile .

For antagonism of EP2 receptors, PF-04418948 is currently the antagonist of choice, having superseded the weaker, non-selective AH-6809 . PF-04418948 demonstrates excellent selectivity for EP2 over other prostanoid receptors in mouse systems and serves as a valuable tool for defining EP2 receptor-mediated responses.

When designing experiments using these pharmacological tools, researchers should always perform concentration-response analyses to determine optimal concentrations for receptor selectivity, include appropriate controls to confirm specificity, and be aware that some compounds may show species differences in potency and selectivity.

How can the functionality of recombinant Ptger2 be validated?

Validating the functionality of recombinant Ptger2 requires a multi-faceted approach employing complementary assays:

Ligand binding assays represent a fundamental validation method, using either radioligand binding with [3H]-PGE2 or fluorescently labeled PGE2 analogs to determine binding affinity (Kd) and receptor density (Bmax). Competition binding assays with known EP2-selective ligands such as ONO-AE1-259 can confirm receptor subtype specificity .

Signaling assays provide critical functional validation. Since Ptger2 couples primarily to Gs proteins, measuring cAMP accumulation following stimulation with PGE2 or selective EP2 agonists provides direct evidence of functional activity . Dose-response curves should yield EC50 values consistent with published data for native receptors. Inhibition of these responses with selective antagonists like PF-04418948 confirms specificity .

Downstream signaling events can further validate receptor functionality. Assessment of CREB phosphorylation by Western blotting following receptor activation provides evidence of intact signaling cascades . This phosphorylation should be concentration-dependent and inhibited by PKA inhibitors or EP2 antagonists.

The most robust validation combines multiple approaches, demonstrating both specific binding and appropriate signal transduction, with comparison to native tissues or cells known to express EP2 as positive controls.

How does Ptger2 signaling affect tumor-infiltrating lymphocytes?

Recent research has revealed that Ptger2 plays a critical role in regulating T cell-mediated anti-tumor immunity, particularly through its effects on stem-like CD8+ T cells. Tumor-derived PGE2 restricts the proliferative expansion and effector differentiation of TCF1+ CD8+ T cells within tumors through EP2 and EP4 receptor signaling . This mechanism contributes significantly to cancer immune escape and may limit the efficacy of current immunotherapies.

A key finding is that PGE2 does not affect the priming of TCF1+ CD8+ T cells in draining lymph nodes but specifically inhibits their function within the tumor microenvironment . This spatial specificity suggests that targeting the PGE2-EP2 axis might enhance anti-tumor immunity without broadly compromising immune responses elsewhere in the body.

Mechanistically, suppression of the interleukin-2 (IL-2) signaling pathway underlies the PGE2-mediated inhibition of TCF1+ tumor-infiltrating lymphocyte (TIL) responses . IL-2 is crucial for T cell proliferation and differentiation, and its impaired signaling effectively constrains anti-tumor immunity.

Remarkably, ablation of EP2/EP4 signaling in cancer-specific CD8+ T cells rescues their expansion and effector differentiation within tumors and has been demonstrated to lead to tumor elimination in multiple mouse cancer models . These findings identify the PGE2–EP2/EP4 axis as a promising molecular target for cancer immunotherapy.

What is the significance of the COX-2/PGE2/EP2 feedback loop in cancer models?

The COX-2/PGE2/EP2 feedback loop represents a critical self-amplifying pathway in cancer models with significant implications for tumor development and progression. This feedback mechanism operates when PGE2 activates EP2 receptors, triggering PKA/CREB signaling that upregulates COX-2 expression . The increased COX-2 then enhances PGE2 production, completing and potentially intensifying the loop .

In skin carcinogenesis models, this feedback loop promotes keratinocyte proliferation and tumor development. EP2 knockout mice show reduced COX-2 expression after TPA treatment compared to wild-type mice, while EP2 transgenic mice exhibit increased COX-2 expression . This relationship directly impacts tumor susceptibility, with reduced tumor development observed in EP2 knockout mice and enhanced tumorigenesis in EP2 overexpressing mice .

The positive feedback nature of this pathway has important therapeutic implications. Interventions that disrupt this loop at different points (COX-2 inhibition, PGE2 synthesis inhibition, or EP2 antagonism) may offer multiple strategies to suppress tumor-promoting inflammation. EP2 antagonists may provide advantages over COX inhibitors by specifically blocking the pathological effects of PGE2 while preserving beneficial prostaglandins .

How can Ptger2 knockout or overexpression models advance cancer research?

Ptger2 knockout and overexpression models provide powerful tools for elucidating this receptor's roles in cancer development and progression. For optimal utilization in cancer research, several approaches should be considered:

Conditional knockout models using Cre-loxP systems enable cell type-specific deletion of Ptger2, which is particularly valuable for dissecting the contributions of EP2 signaling in different cellular compartments (e.g., epithelial cells, endothelial cells, or specific immune cell subsets) . This approach can distinguish between direct effects on cancer cells versus effects on the tumor microenvironment.

For mechanistic investigations, ex vivo analysis of cells from knockout or overexpression models provides insights into altered signaling pathways and cellular functions. Techniques such as phospho-flow cytometry, RNA-seq, and proteomics can comprehensively characterize molecular changes resulting from modulated EP2 signaling .

Therapeutic relevance can be assessed by combining knockout models with standard treatments or immunotherapies to identify synergistic effects, suggesting potential combinatorial approaches for clinical development . These studies can help identify patient populations most likely to benefit from EP2-targeted interventions.

What controls are essential when studying Ptger2-mediated effects?

When studying Ptger2-mediated effects, particularly in complex systems like immune responses or tumor models, several essential controls should be included to ensure results are specific and interpretable:

Genetic controls are fundamental, including Ptger2 knockout cells or tissues as negative controls to confirm receptor specificity . When possible, reconstitution of Ptger2 expression in knockout cells provides powerful validation by demonstrating rescue of the phenotype. Cells expressing mutant Ptger2 with impaired signaling capacity can help distinguish between signaling-dependent and independent effects.

Pharmacological controls should include vehicle controls matching the solvent used for PGE2 or other EP2 modulators, concentration gradients to establish dose-dependence, and selective EP2 antagonists (e.g., PF-04418948) to confirm receptor specificity . Parallel studies with selective agonists/antagonists for other EP receptors help rule out contributions from those receptors. Downstream pathway inhibitors (e.g., PKA inhibitors) further confirm specific signaling mechanisms .

Biological controls might compare different cell subsets (e.g., CD4+ vs. CD8+ T cells) to identify subset-specific responses , include time-course experiments to distinguish immediate from delayed effects, and compare cells from different anatomical locations (e.g., tumor vs. draining lymph node) to assess contextual differences .

The most robust experimental designs incorporate multiple types of controls to triangulate findings and provide comprehensive validation of Ptger2-mediated effects.

How can researchers distinguish between Ptger2-specific effects and those of other PGE2 receptors?

Distinguishing between Ptger2-specific effects and those mediated by other PGE2 receptors (EP1, EP3, EP4) requires strategic experimental approaches combining genetic, pharmacological, and signaling analysis techniques:

Genetic approaches provide the most definitive evidence for receptor specificity. Using Ptger2 knockout mice or cells with CRISPR-mediated Ptger2 deletion for loss-of-function studies eliminates EP2-mediated effects . Comparing phenotypes across individual EP receptor knockout models can further identify receptor-specific contributions. Reconstitution experiments where wild-type or mutant Ptger2 is reintroduced into Ptger2-null backgrounds provide additional validation.

Pharmacological approaches complement genetic strategies through the application of receptor subtype-selective agonists like ONO-AE1-259 for EP2 and receptor subtype-selective antagonists such as PF-04418948 for EP2 . Combination approaches where multiple receptors are selectively blocked can isolate individual receptor contributions when multiple EP receptors are expressed in the system of interest.

Signaling pathway analysis leverages the distinct coupling preferences of different EP receptors: EP2 and EP4 primarily couple to Gs/cAMP/PKA, while EP1 couples to Gq/calcium and EP3 mainly to Gi . Measuring pathway-specific second messengers (cAMP for EP2/EP4, calcium for EP1, inhibition of cAMP for EP3) and receptor-specific downstream targets (e.g., CREB phosphorylation for EP2/EP4) can differentiate between receptor subtypes based on their signaling profiles.

The most convincing demonstrations of EP2-specific effects combine multiple complementary approaches rather than relying solely on any single method.

What are common pitfalls when interpreting Ptger2 research findings?

When interpreting Ptger2 research findings, particularly in complex in vivo models, researchers should be aware of several common pitfalls:

Compensatory mechanisms represent a significant challenge, as genetic deletion or chronic inhibition of Ptger2 may trigger upregulation of other EP receptors (EP1, EP3, EP4) or alternative signaling pathways that compensate for lost EP2 function . This compensation can mask or confound phenotypes. Always assess expression of other EP receptors in Ptger2 knockout models and consider using inducible knockout systems to minimize compensatory adaptations.

Cell type heterogeneity complicates interpretation since EP2 receptors are expressed on multiple cell types, including various immune cells, epithelial cells, and stromal components . Global Ptger2 deletion or systemic EP2 antagonist administration affects all these populations simultaneously. Cell type-specific knockout models or adoptive transfer approaches are essential to isolate cell-specific contributions .

Pharmacological specificity issues arise when "selective" EP2 agonists or antagonists exhibit activity at other prostanoid receptors at higher concentrations . Always validate pharmacological findings with genetic approaches and use the minimum effective concentration of compounds with careful dose-response characterization.

Context-dependent signaling means EP2 outcomes may differ dramatically depending on the inflammatory milieu, tissue microenvironment, or disease stage . Carefully control and report these contextual factors and avoid generalizing findings across different models without validation.

Secondary mediator effects occur when EP2 signaling affects production of numerous cytokines and inflammatory mediators that may themselves drive phenotypes . Distinguish direct EP2 signaling effects from those mediated by secondary factors through rescue experiments or blocking secondary mediators.

How can Ptger2 research inform cancer immunotherapy approaches?

Research on Ptger2 has significant implications for advancing cancer immunotherapy approaches, particularly through enhancing T cell-mediated anti-tumor immunity. Several key findings point toward promising therapeutic strategies:

The discovery that tumor-derived PGE2 restricts TCF1+ stem-like CD8+ T cell responses through EP2/EP4 signaling identifies a critical immune evasion mechanism . This mechanism specifically limits the expansion and differentiation of tumor-infiltrating lymphocytes with stemness properties, which are crucial for sustained anti-tumor responses and responsiveness to checkpoint inhibition. Targeting the PGE2-EP2 axis could potentially enhance the efficacy of existing immunotherapies by preserving these stem-like T cell populations.

Importantly, the observation that PGE2 does not affect T cell priming in draining lymph nodes but specifically inhibits their function within tumors suggests that EP2 targeting might enhance anti-tumor immunity without broadly compromising immune responses elsewhere . This spatial specificity could translate to a favorable therapeutic window.

Mechanistically, EP2 signaling suppresses IL-2 responsiveness in tumor-infiltrating T cells . Since IL-2 signaling is fundamental for T cell proliferation and effector function, interventions that restore IL-2 responsiveness by blocking EP2 could reinvigorate exhausted or dysfunctional TILs. This approach might be particularly valuable in "cold" tumors with limited T cell infiltration or activation.

Preclinical studies have demonstrated that genetic ablation of EP2/EP4 signaling in cancer-specific CD8+ T cells rescues their expansion and effector differentiation within tumors, leading to tumor elimination in multiple mouse cancer models . This suggests that pharmacological inhibition of these receptors could yield similar benefits in a therapeutic context.

EP2 antagonists could potentially synergize with existing immunotherapies including checkpoint inhibitors, adoptive cell therapies, and cancer vaccines by removing a key immunosuppressive pathway within the tumor microenvironment.

What methodological advances are improving Ptger2 functional studies?

Recent methodological advances have significantly enhanced our ability to study Ptger2 function across multiple research contexts:

Improved recombinant protein expression systems now allow for more efficient production of functional Ptger2 protein. Optimized mammalian expression systems using HEK-293 cells with appropriate tags (His, Strep, or Fc) have enhanced protein yield and purity . Cell-free protein synthesis (CFPS) systems represent another advance, enabling rapid production of membrane proteins like Ptger2 without the limitations of cellular expression systems .

Enhanced pharmacological tools have dramatically improved receptor targeting specificity. The development of highly selective EP2 agonists like ONO-AE1-259 and antagonists like PF-04418948 has replaced older, less selective compounds, enabling more precise interrogation of EP2-specific functions . These tools allow researchers to distinguish between effects mediated by EP2 versus other PGE2 receptors.

Single-cell technologies now permit analysis of EP2 signaling at unprecedented resolution. Single-cell RNA sequencing, mass cytometry (CyTOF), and phospho-flow cytometry enable researchers to dissect heterogeneous responses to EP2 activation within complex cell populations, particularly important in tumor microenvironments and immune contexts .

CRISPR-Cas9 genome editing has revolutionized the generation of cellular and animal models for studying Ptger2. This technology allows for precise receptor knockout or mutation, including the introduction of specific point mutations to study structure-function relationships. Inducible CRISPR systems further enable temporal control of gene editing to minimize developmental or compensatory effects.

Advanced imaging techniques including intravital microscopy allow real-time visualization of immune cell behaviors following modulation of EP2 signaling in living tissues. This approach is particularly valuable for understanding how EP2 signaling affects T cell trafficking, interactions, and function within tumor microenvironments .